JP5813321B2 - 体細胞の再プログラム化 - Google Patents

体細胞の再プログラム化 Download PDF

Info

Publication number
JP5813321B2
JP5813321B2 JP2010501136A JP2010501136A JP5813321B2 JP 5813321 B2 JP5813321 B2 JP 5813321B2 JP 2010501136 A JP2010501136 A JP 2010501136A JP 2010501136 A JP2010501136 A JP 2010501136A JP 5813321 B2 JP5813321 B2 JP 5813321B2
Authority
JP
Japan
Prior art keywords
cells
cell
potential
pluripotent
somatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010501136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521990A5 (OSRAM
JP2010521990A (ja
Inventor
ジェイムズ トムソン
ジェイムズ トムソン
ジュンイン ユー
ジュンイン ユー
Original Assignee
ウィスコンシン アラムニ リサーチ ファンデーション
ウィスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5813321(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ウィスコンシン アラムニ リサーチ ファンデーション, ウィスコンシン アラムニ リサーチ ファンデーション filed Critical ウィスコンシン アラムニ リサーチ ファンデーション
Publication of JP2010521990A publication Critical patent/JP2010521990A/ja
Publication of JP2010521990A5 publication Critical patent/JP2010521990A5/ja
Application granted granted Critical
Publication of JP5813321B2 publication Critical patent/JP5813321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010501136A 2007-03-23 2008-03-21 体細胞の再プログラム化 Active JP5813321B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US91968707P 2007-03-23 2007-03-23
US60/919,687 2007-03-23
US97498007P 2007-09-25 2007-09-25
US60/974,980 2007-09-25
US98905807P 2007-11-19 2007-11-19
US60/989,058 2007-11-19
PCT/US2008/057924 WO2008118820A2 (en) 2007-03-23 2008-03-21 Somatic cell reprogramming

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015094203A Division JP6788329B2 (ja) 2007-03-23 2015-05-01 体細胞の再プログラム化

Publications (3)

Publication Number Publication Date
JP2010521990A JP2010521990A (ja) 2010-07-01
JP2010521990A5 JP2010521990A5 (OSRAM) 2011-04-14
JP5813321B2 true JP5813321B2 (ja) 2015-11-17

Family

ID=39708430

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010501136A Active JP5813321B2 (ja) 2007-03-23 2008-03-21 体細胞の再プログラム化
JP2015094203A Active JP6788329B2 (ja) 2007-03-23 2015-05-01 体細胞の再プログラム化
JP2018147683A Active JP6924732B2 (ja) 2007-03-23 2018-08-06 体細胞の再プログラム化
JP2018147684A Pending JP2018183183A (ja) 2007-03-23 2018-08-06 体細胞の再プログラム化
JP2021126772A Pending JP2021176331A (ja) 2007-03-23 2021-08-02 体細胞の再プログラム化
JP2024010931A Pending JP2024038501A (ja) 2007-03-23 2024-01-29 体細胞の再プログラム化

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015094203A Active JP6788329B2 (ja) 2007-03-23 2015-05-01 体細胞の再プログラム化
JP2018147683A Active JP6924732B2 (ja) 2007-03-23 2018-08-06 体細胞の再プログラム化
JP2018147684A Pending JP2018183183A (ja) 2007-03-23 2018-08-06 体細胞の再プログラム化
JP2021126772A Pending JP2021176331A (ja) 2007-03-23 2021-08-02 体細胞の再プログラム化
JP2024010931A Pending JP2024038501A (ja) 2007-03-23 2024-01-29 体細胞の再プログラム化

Country Status (11)

Country Link
US (7) US8440461B2 (OSRAM)
EP (2) EP2137296A2 (OSRAM)
JP (6) JP5813321B2 (OSRAM)
KR (1) KR101516833B1 (OSRAM)
CN (1) CN101743306A (OSRAM)
AU (1) AU2008231020B2 (OSRAM)
CA (1) CA2684242C (OSRAM)
DK (1) DK3399025T3 (OSRAM)
IL (1) IL200982A (OSRAM)
SG (2) SG193652A1 (OSRAM)
WO (1) WO2008118820A2 (OSRAM)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
SE531979C2 (sv) 2005-06-01 2009-09-22 Wisconsin Alumni Res Found Metod för att framställa dendritiska celler från mänskliga embryonala stamceller, samt odlingar framställda med metoden
US8034613B2 (en) 2005-06-01 2011-10-11 Wisconsin Alumni Research Foundation Multipotent lymphohematopoietic progenitor cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8158422B2 (en) * 2006-02-09 2012-04-17 Wisconsin Alumni Research Foundation Erythroid cells producing adult-type β-hemoglobin generated from human embryonic stem cells
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CN101932705A (zh) 2007-04-07 2010-12-29 怀特黑德生物医学研究所 体细胞重编程
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20110236971A2 (en) * 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
CA2660123C (en) * 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
US9683232B2 (en) * 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
CA2723820A1 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
JP2011522540A (ja) * 2008-06-04 2011-08-04 セルラー ダイナミクス インターナショナル， インコーポレイテッド 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
WO2009152529A2 (en) 2008-06-13 2009-12-17 Whitehead Institute For Biomedical Research Nine Cambridge Center Programming and reprogramming of cells
CN101835890B (zh) 2008-06-27 2013-07-24 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
CN101848994A (zh) * 2008-07-30 2010-09-29 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
EP2331696A1 (en) * 2008-08-12 2011-06-15 Cellular Dynamics International, Inc. Methods for the production of ips cells
US20120021519A1 (en) * 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010042800A1 (en) * 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
EP2356221B1 (en) 2008-10-24 2018-11-21 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
WO2010050626A1 (en) * 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
US9045737B2 (en) * 2008-12-13 2015-06-02 Dnamicroarray, Inc. Artificial three-dimensional microenvironment niche culture
US20110300627A1 (en) * 2009-01-20 2011-12-08 Sing George L Dedifferentiation and reprogramming of cells
CA2753208C (en) 2009-02-20 2018-08-21 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
WO2010098419A1 (en) * 2009-02-27 2010-09-02 Kyoto University Novel nuclear reprogramming substance
CA2755870C (en) * 2009-03-20 2019-04-09 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
EP2421957B1 (en) 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
EP2548950B1 (en) 2009-06-05 2017-10-25 Cellular Dynamics International, Inc. Reprogramming T cells and hematopoietic cells
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
JP5645197B2 (ja) * 2009-06-23 2014-12-24 学校法人日本大学 幹細胞の未分化状態を維持する新規方法
US8709805B2 (en) 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same
CA2770412C (en) 2009-08-07 2018-09-11 Kyoto University Method of efficiently establishing induced pluripotent stem cells
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
WO2011037270A1 (en) 2009-09-24 2011-03-31 Kyoto University Method of efficiently establishing induced pluripotent stem cells
GB2474492B (en) * 2009-10-19 2014-05-21 Tristem Trading Cyprus Ltd Treatment using reprogrammed mature adult cells
CA2779039A1 (en) 2009-10-29 2011-05-05 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
PH12012500818A1 (en) * 2009-10-29 2019-11-29 Janssen Biotech Inc Pluripotent stem cells
WO2011056971A2 (en) * 2009-11-04 2011-05-12 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
EP2511366A4 (en) 2009-12-09 2014-04-30 Univ Kyoto NITROVINE MEDICINE FOR PROMOTING THE DIFFERENTIATION OF PLURIPOTENTAL STEM CELLS IN HEART MUSCLES
WO2011074690A1 (en) 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
JP5827220B2 (ja) 2010-01-22 2015-12-02 国立大学法人京都大学 人工多能性幹細胞の樹立効率改善方法
CA2789749C (en) 2010-02-16 2018-09-04 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN102190731B (zh) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 用人工转录因子诱导产生多能干细胞
EP2547768B1 (en) 2010-03-17 2015-12-30 Association Institut de Myologie Modified u7 snrnas for treatment of neuromuscular diseases
WO2011118655A1 (ja) * 2010-03-23 2011-09-29 オリンパス株式会社 幹細胞の分化状態をモニタリングする方法
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
CN106381280B (zh) * 2010-05-13 2020-08-04 加州大学董事会 用于诱导人类多能干细胞的方法和组合物
JP5936134B2 (ja) 2010-06-15 2016-06-15 国立大学法人京都大学 ヒト人工多能性幹細胞の選択方法
AU2011267849B2 (en) 2010-06-15 2015-02-05 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2012020687A1 (en) 2010-08-13 2012-02-16 Kyoto University Method of inducing differentiation from pluripotent stem cells to germ cells
CA2838330C (en) 2010-08-23 2021-01-26 President And Fellows Of Harvard College Optogenetic probes for measuring membrane potential
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
CN103209968B (zh) 2010-08-26 2015-08-05 国立大学法人京都大学 多能干细胞心肌细胞分化促进剂
WO2012029994A1 (en) 2010-09-02 2012-03-08 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
JP5794588B2 (ja) 2010-09-14 2015-10-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN103459611B (zh) 2010-09-17 2016-11-02 哈佛大学校长及研究员协会 对多能干细胞的效用和安全性进行表征的功能基因组学研究
EP2630232A4 (en) 2010-10-22 2014-04-02 Biotime Inc METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS
EP2647699B1 (en) 2010-12-03 2020-04-01 Kyoto University Efficient method for establishing induced pluripotent stem cells
WO2012100084A1 (en) 2011-01-19 2012-07-26 The Regents Of The University Of California Somatic cells with innate potential for pluripotency
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
EP2695894B1 (en) 2011-04-08 2017-11-01 Osaka University Modified laminin and use thereof
WO2012141181A1 (ja) * 2011-04-11 2012-10-18 国立大学法人京都大学 核初期化物質
US9133266B2 (en) 2011-05-06 2015-09-15 Wisconsin Alumni Research Foundation Vitronectin-derived cell culture substrate and uses thereof
KR101791926B1 (ko) 2011-07-25 2017-11-20 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도 만능 줄기 세포 스크리닝 방법
WO2013028702A1 (en) * 2011-08-22 2013-02-28 Mayo Foundation For Medical Education And Research Methods and materials for obtaining induced pluripotent stem cells
US20130058905A1 (en) 2011-08-23 2013-03-07 Igor Slukvin Angiohematopoietic Progenitor Cells
WO2013055834A2 (en) * 2011-10-11 2013-04-18 The New York Stem Cell Foundation Er stress relievers in beta cell protection
US20140248698A1 (en) 2011-10-21 2014-09-04 Arkray, Inc. Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
EP2784153B1 (en) 2011-11-25 2018-01-03 Kyoto University Method for culturing pluripotent stem cell
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US10238755B2 (en) 2011-11-30 2019-03-26 The Wistar Institute Of Anatomy And Biology Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
MX354995B (es) 2011-12-05 2018-03-27 Factor Bioscience Inc Metodos y productos para transfeccion de celulas.
WO2013090919A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
WO2013111875A1 (ja) 2012-01-27 2013-08-01 国立大学法人京都大学 多能性幹細胞の心筋分化誘導法
AU2013264708B2 (en) 2012-05-23 2019-03-07 Kyoto University Highly efficient method for establishing artificial pluripotent stem cell
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9175263B2 (en) 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
US20150267174A1 (en) 2012-10-09 2015-09-24 Nakanobu Hayashi Reprogramming peptide and use thereof
WO2014065435A1 (en) 2012-10-23 2014-05-01 Kyoto University Method of efficiently establishing induced pluripotent stem cells
KR102315098B1 (ko) 2012-11-01 2021-10-21 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
DK3766962T3 (da) 2013-02-06 2025-11-17 Univ Rochester Inducerede, pluripotente, celleafledte oligodendrocyt-progenitorceller til behandling af myelinforstyrrelser
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
US9738861B2 (en) 2013-03-06 2017-08-22 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
JP6351567B2 (ja) 2013-03-08 2018-07-04 国立大学法人京都大学 Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤
MX366900B (es) 2013-03-13 2019-07-30 Wisconsin Alumni Res Found Métodos y materiales para diferenciación hematoendotelial de células germinales pluripotentes humanas bajo condiciones definidas.
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10519421B2 (en) 2013-03-21 2019-12-31 Kyoto University Induction of motor neurons from pluripotent stem cells
JP6473686B2 (ja) 2013-03-25 2019-02-20 公益財団法人神戸医療産業都市推進機構 細胞の選別方法
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
EP2998391B1 (en) 2013-05-14 2020-02-19 Kyoto University Efficient myocardial cell induction method
KR101870174B1 (ko) 2013-05-31 2018-06-22 아이하트 재팬 가부시키가이샤 하이드로겔을 포함하는 적층화된 세포 시트
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11085067B2 (en) 2013-06-10 2021-08-10 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
MX2015017036A (es) 2013-06-11 2016-07-21 Univ Kyoto Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas.
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
CN121136933A (zh) 2013-09-05 2025-12-16 国立大学法人京都大学 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒
US20160222347A1 (en) 2013-09-12 2016-08-04 Kaneka Corporation Method for inducing differentiation of induced pluripotent stem cells and method for selecting the same
JP6333830B2 (ja) 2013-09-13 2018-05-30 国立大学法人京都大学 多能性幹細胞の心筋分化を促進する化合物
EP3064577B1 (en) 2013-11-01 2020-09-09 Kyoto University Novel chondrocyte induction method
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US11377639B2 (en) 2013-11-15 2022-07-05 Wisconsin Alumni Research Foundation Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
EP3080248A1 (en) 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
RU2714404C2 (ru) 2014-01-31 2020-02-14 Фэктор Байосайенс Инк. Способы и продукты для получения и доставки нуклеиновых кислот
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10233426B2 (en) 2014-05-30 2019-03-19 Kyoto University Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
EP3929302A1 (en) 2014-07-14 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
CN107075484B (zh) 2014-07-18 2022-01-28 国立大学法人京都大学 从多能性干细胞诱导细胞免疫治疗用t细胞的方法
EP3194571A4 (en) 2014-09-18 2018-04-18 North Carolina State University Mammalian lung spheroids and lung spheroid cells and uses thereof
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CA2963934C (en) * 2014-10-06 2023-05-09 Memorial Sloan-Kettering Cancer Center Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors
JP6865167B2 (ja) 2014-12-17 2021-04-28 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
PT3233129T (pt) 2014-12-17 2020-04-15 Fundacion Para La Investig Medica Aplicada Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
EP3246406B1 (en) 2015-01-16 2022-03-09 National Institute of Advanced Industrial Science and Technology Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
JP6983762B2 (ja) 2015-09-08 2021-12-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 臨床グレードの網膜色素上皮細胞の再現性のある分化のための方法
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
US10947502B2 (en) 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
SG11201804197RA (en) 2015-11-18 2018-06-28 Orbis Health Solutions Llc T7 alpha viral vector system
US10450574B2 (en) * 2015-11-24 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Transient transfection method for retroviral production
CN115433707A (zh) 2015-12-07 2022-12-06 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
EP3431584B1 (en) 2016-03-18 2023-06-28 Kyoto University Methods for freezing an aggregate of pluripotent stem cell-derived cardiomyocytes
AU2017248985B2 (en) 2016-04-15 2023-01-12 Kyoto University Method for inducing antigen specific CD8 positive T cells
CN109072198B (zh) 2016-04-22 2022-08-26 国立大学法人京都大学 产多巴胺神经祖细胞的制备方法
US11352605B2 (en) 2016-05-12 2022-06-07 Erasmus University Medical Center Rotterdam Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
CN105861447B (zh) * 2016-06-13 2017-12-19 广州市搏克生物技术有限公司 一种非病毒iPSCs诱导组合物及其试剂盒
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
CN105936889B (zh) * 2016-06-24 2019-10-18 肇庆大华农生物药品有限公司 一种ad293球形细胞团的培养方法
EP3478325B1 (en) 2016-07-01 2024-07-17 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
KR102537361B1 (ko) 2016-12-27 2023-05-26 스미또모 가가꾸 가부시키가이샤 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
EP3575392A4 (en) 2017-01-26 2020-08-26 Osaka University MEDIUM INTENDED TO INDUCE DIFFERENTIATION OF STEM CELLS INTO MESODERMAL CELLS AND PROCESS INTENDED TO PRODUCE MESODERMAL CELLS
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
JP7171055B2 (ja) 2017-03-14 2022-11-15 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN110913689A (zh) 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
JP7161775B2 (ja) 2017-05-25 2022-10-27 国立大学法人京都大学 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法
EP3640318A4 (en) 2017-06-14 2021-03-17 Takeda Pharmaceutical Company Limited CELL SEALING DEVICE
JP6758631B2 (ja) 2017-06-19 2020-09-23 国立大学法人大阪大学 角膜内皮細胞マーカー及びその利用
CN111164209A (zh) 2017-06-19 2020-05-15 公益财团法人神户医疗产业都市推进机构 多能干细胞的分化能力的预测方法和用于该预测方法的试剂
US10760057B2 (en) 2017-07-06 2020-09-01 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease
US11718829B2 (en) * 2017-07-28 2023-08-08 Breakthrough Tech Llc Methods and compositions for manufacturing extracellular matrix
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
JP7140400B2 (ja) 2017-10-17 2022-09-21 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
AU2018375192B2 (en) 2017-12-01 2023-11-09 Encoded Therapeutics, Inc. Engineered DNA binding proteins
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
JPWO2019182157A1 (ja) 2018-03-19 2021-03-18 国立大学法人京都大学 ハイドロゲルカプセル
CA3097962A1 (en) 2018-04-23 2019-10-31 Kyoto University Growth inhibitor
WO2019246112A1 (en) 2018-06-18 2019-12-26 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
CA3103675A1 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
WO2020013315A1 (ja) 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
JP7285015B2 (ja) 2018-07-19 2023-06-01 国立大学法人京都大学 多能性幹細胞由来の板状軟骨およびその製造方法
EP3828262A4 (en) 2018-07-23 2022-03-30 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
AU2019318021B2 (en) 2018-08-10 2025-01-30 Kyoto University Method for producing CD3-positive cell
WO2020051453A1 (en) 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CA3116098A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
AU2019375450A1 (en) 2018-11-07 2021-06-17 Vivet Therapeutics Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
WO2020102715A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Method for t cell de-differentiation and resulting cells
CN113302290A (zh) 2018-11-16 2021-08-24 编码治疗公司 治疗威尔逊氏病的组合物和方法
CN120555349A (zh) 2018-11-16 2025-08-29 拉帕治疗有限公司 使用诱导性调节性T（iTREG）细胞进行的ALS治疗
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2020116606A1 (ja) 2018-12-06 2020-06-11 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤
CN113728103B (zh) 2018-12-11 2025-02-28 罗切斯特大学 治疗精神分裂症和其他神经精神病症的方法
US12435311B2 (en) 2018-12-21 2025-10-07 The University Of Osaka Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
CN113226475A (zh) 2018-12-26 2021-08-06 麒麟控股株式会社 改造tcr及其制造方法
US20230057355A1 (en) 2019-02-13 2023-02-23 University Of Rochester Gene networks that mediate remyelination of the human brain
JP7692610B2 (ja) 2019-02-26 2025-06-16 国立大学法人東北大学 ｉＰＳ細胞を用いた骨芽細胞塊の作製法
KR20220008894A (ko) 2019-05-15 2022-01-21 아지노모토 가부시키가이샤 신경제세포 또는 각막 상피 세포의 순화 방법
JPWO2020235319A1 (OSRAM) 2019-05-20 2020-11-26
TWI872078B (zh) 2019-05-29 2025-02-11 美商編碼製藥公司 用於選擇性基因調節的組合物和方法
CN114450265B (zh) 2019-07-03 2024-12-24 菲克特生物科学股份有限公司 阳离子脂质及其用途
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP7058431B2 (ja) 2019-12-12 2022-04-22 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
BR112022017216A2 (pt) 2020-02-28 2022-10-11 Takeda Pharmaceuticals Co Método para produzir células exterminadoras naturais a partir de células-tronco pluripotentes
JPWO2021200901A1 (OSRAM) 2020-03-31 2021-10-07
US20230203445A1 (en) 2020-05-26 2023-06-29 Healios K.K. Hypoimmunogenic cells
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
WO2021256522A1 (ja) 2020-06-17 2021-12-23 国立大学法人京都大学 キメラ抗原受容体発現免疫担当細胞
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
EP4180514A4 (en) 2020-07-20 2024-09-04 Aichi Medical University COMPOSITION FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, MEDIUM FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, METHOD FOR MAINTENANCE CULTURE IN UNDIFFERENTIATED STATE OF PLURIPOTENT CELLS, AND METHOD FOR PRODUCING PLURIPOTENT CELLS
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
JPWO2022039279A1 (OSRAM) 2020-08-18 2022-02-24
US20230220025A1 (en) 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
CN116323941A (zh) 2020-09-29 2023-06-23 吉尼松公司 通过诱导抗肌萎缩蛋白相关蛋白调节元件内的突变增强细胞中抗肌萎缩蛋白相关蛋白表达及其治疗用途
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022129430A1 (en) 2020-12-16 2022-06-23 Universitat Pompeu Fabra Therapeutic lama2 payload for treatment of congenital muscular dystrophy
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
EP4310176A4 (en) 2021-03-17 2025-03-26 Astellas Pharma Inc. Pericyte with basic fibroblast growth factor (BFGF) gene inserted into it
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
US20240216440A1 (en) 2021-04-30 2024-07-04 Riken String-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said string-like aggregates
WO2022255489A1 (ja) 2021-06-04 2022-12-08 キリンホールディングス株式会社 細胞組成物、細胞組成物の製造方法及び細胞組成物を含む医薬組成物
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
CA3222770A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023286834A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
WO2023003025A1 (ja) 2021-07-21 2023-01-26 国立大学法人京都大学 網膜組織の製造方法
EP4386083A4 (en) 2021-08-11 2025-11-12 Univ Kyoto METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS AND METHOD FOR PRODUCING RENIIN-PRODUCING CELLS
KR20240056604A (ko) 2021-09-13 2024-04-30 후지필름 셀룰러 다이내믹스, 인코포레이티드 수임 심장 전구세포의 제조 방법
US20240400622A1 (en) 2021-09-23 2024-12-05 President And Fellows Of Harvard College Genetically encoded voltage indicators and uses thereof
WO2023053220A1 (ja) 2021-09-28 2023-04-06 公益財団法人京都大学ｉＰＳ細胞研究財団 多能性幹細胞の製造方法
JP2024539672A (ja) * 2021-10-18 2024-10-29 ウィスコンシン アラムニ リサーチ ファンデーション ヒト体細胞リプログラミングのラベルフリー追跡のためのシステム及び方法
CA3234404A1 (en) 2021-10-20 2023-04-27 Steven A. Goldman Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
EP4419655A1 (en) 2021-10-20 2024-08-28 University of Rochester Humanized chimeras for the prospective assessment of cell addition and replacement therapies
WO2023069987A1 (en) 2021-10-20 2023-04-27 University Of Rochester Rejuvenation treatment of age-related white matter loss cross reference to related application
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
CN118265792A (zh) 2021-11-11 2024-06-28 希里欧斯株式会社 基因修饰多能干细胞、来自其的免疫活性细胞、它们的制造方法和它们的用途
EP4472648A1 (en) 2022-02-01 2024-12-11 University of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
JPWO2023153464A1 (OSRAM) 2022-02-09 2023-08-17
WO2023210713A1 (ja) 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法
US20250276020A1 (en) 2022-05-05 2025-09-04 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
CA3257424A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically modified cells expressing variants of CD16 and NKG2D and their uses
US20250376727A1 (en) 2022-06-10 2025-12-11 Kyoto University Detection method and detection reagent for undifferentiated pluripotent stem cells
US20250361285A1 (en) 2022-07-26 2025-11-27 Kyoto University Artificial receptor having shedding structure
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
JPWO2024157929A1 (OSRAM) 2023-01-23 2024-08-02
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2024248017A1 (ja) 2023-05-29 2024-12-05 国立研究開発法人理化学研究所 心筋細胞を成熟させる方法及び成熟した心筋細胞の製造方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US20040199935A1 (en) * 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
AU6842001A (en) * 2000-06-15 2001-12-24 Tanja Dominko Pluripotent mammalian cells
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
WO2003018780A1 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JP2004248505A (ja) 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
ITMI20012110A1 (it) 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
EP1468094A4 (en) 2001-12-24 2005-01-26 Es Cell Int Pte Ltd METHOD OF TRANSDUCTING ES CELLS
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
DK1503788T3 (da) * 2002-04-25 2011-10-17 Shire Human Genetic Therapies Behandling af alpha-galactosidase A-deficiens
ES2705683T3 (es) * 2002-12-16 2019-03-26 Technion Res & Dev Foundation Medio de cultivo de células madre pluripotentes
US20060128018A1 (en) 2003-02-07 2006-06-15 Zwaka Thomas P Directed genetic modifications of human stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7638331B2 (en) * 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
EP1730261A4 (en) * 2004-03-10 2007-11-28 Univ California COMPOSITIONS AND METHODS FOR GROWING EMBRYONIC STEM CELLS
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
US7465580B2 (en) 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
PE20060302A1 (es) 2004-06-18 2006-04-08 Glaxo Group Ltd Derivados de benzazepina como antagonistas del receptor h3
US7566548B2 (en) * 2004-08-13 2009-07-28 University Of Massachusetts Methods for identifying therapeutic agents and for treating disease
EP1984487B1 (en) * 2005-08-03 2022-10-12 Astellas Institute for Regenerative Medicine Improved methods of reprogramming animal somatic cells
US20080199849A1 (en) 2005-09-02 2008-08-21 Agency For Science, Technology And Research Method of Deriving Progenitor Cell Line
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JP4803584B2 (ja) 2006-02-08 2011-10-26 独立行政法人産業技術総合研究所 脂質生産性の高い形質転換微生物
AU2007277863A1 (en) 2006-07-07 2008-01-31 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome (HAC) vector, and human cell pharmaceutical comprising human artificial chromosome (HAC) vector
EP2054079A4 (en) 2006-07-19 2009-12-23 Univ Florida COMPOSITIONS FOR CELL REPROGRAMMING AND USES THEREOF
WO2008020595A1 (en) 2006-08-15 2008-02-21 Ishihara Sangyo Kaisha, Ltd. Novel method for utilization of microbial mutant
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
JP2008067693A (ja) 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
US20100069251A1 (en) 2006-09-15 2010-03-18 Children's Medical Center Corporation Methods for producing embryonic stem cells from parthenogenetic embryos
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
JP2010528613A (ja) 2007-05-29 2010-08-26 クリストファー ビー． リード， 多能細胞集団を産生する方法およびその使用
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
US20110236971A2 (en) 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
WO2009058712A1 (en) * 2007-10-29 2009-05-07 Trustees Of Dartmouth College Toxoplasma gondii mutant with enhanced homologous recombination and uses thereof
CA2660123C (en) 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) * 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2009091543A1 (en) 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
WO2009092042A1 (en) 2008-01-18 2009-07-23 Nevada Cancer Institute Reprogramming of differentiated progenitor or somatic cells using homologous recombination
WO2009102983A2 (en) * 2008-02-15 2009-08-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
JP2011522540A (ja) 2008-06-04 2011-08-04 セルラー ダイナミクス インターナショナル， インコーポレイテッド 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
WO2010012077A1 (en) 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
EP2331696A1 (en) 2008-08-12 2011-06-15 Cellular Dynamics International, Inc. Methods for the production of ips cells
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
EP2356221B1 (en) 2008-10-24 2018-11-21 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming

Also Published As

Publication number Publication date
US20110028537A1 (en) 2011-02-03
AU2008231020A1 (en) 2008-10-02
CN101743306A (zh) 2010-06-16
JP2018183183A (ja) 2018-11-22
US20130210138A1 (en) 2013-08-15
SG193653A1 (en) 2013-10-30
JP2021176331A (ja) 2021-11-11
US20190106675A1 (en) 2019-04-11
US8183038B2 (en) 2012-05-22
JP6924732B2 (ja) 2021-08-25
EP2137296A2 (en) 2009-12-30
CA2684242C (en) 2019-11-12
SG193652A1 (en) 2013-10-30
WO2008118820A2 (en) 2008-10-02
US8440461B2 (en) 2013-05-14
US9499786B2 (en) 2016-11-22
IL200982A0 (en) 2010-05-17
US11898162B2 (en) 2024-02-13
AU2008231020B2 (en) 2013-09-05
US20240271087A1 (en) 2024-08-15
EP3399025B1 (en) 2025-05-07
KR101516833B1 (ko) 2015-05-07
DK3399025T3 (da) 2025-06-16
US20200239840A1 (en) 2020-07-30
JP2015165810A (ja) 2015-09-24
US20080233610A1 (en) 2008-09-25
IL200982A (en) 2013-03-24
US20140057355A1 (en) 2014-02-27
EP3399025A1 (en) 2018-11-07
WO2008118820A3 (en) 2008-11-20
JP2024038501A (ja) 2024-03-19
JP2010521990A (ja) 2010-07-01
KR20090126303A (ko) 2009-12-08
US10106772B2 (en) 2018-10-23
JP2018183182A (ja) 2018-11-22
JP6788329B2 (ja) 2020-11-25
CA2684242A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
US20240271087A1 (en) Somatic Cell Reprogramming
EP2476750A1 (en) Somatic cell reprogramming
US10221396B2 (en) Reprogramming T cells and hematopoietic cells
CN102190731B (zh) 用人工转录因子诱导产生多能干细胞
AU2015200413B2 (en) Reprogramming t cells and hematopoietic cells
Zaehres et al. Induced pluripotent stem cells
AU2016200360B2 (en) Somatic cell reprogramming
AU2013267048B2 (en) Somatic cell reprogramming
HK1172057A (en) Somatic cell reprogramming

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140421

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150916

R150 Certificate of patent or registration of utility model

Ref document number: 5813321

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250